Claims
- 1. A compound which is N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitro benzamide; or a salt thereof, or a solvate thereof.
- 2. A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier.
- 3. A method for the treatment and/or prophylaxis of arrhythmia and ischaemic rhythm disorders in a human or non-human mammal which comprises administering an effective, non-toxic, amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof to a human or non-human mammal in need thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
94 12806 |
Oct 1994 |
FRX |
|
Parent Case Info
This application is a 371 of PCT/EP95/04203, filed Oct. 24, 1995.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/EP95/04203 |
10/24/1995 |
|
|
7/2/1997 |
7/2/1997 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO96/13479 |
5/9/1996 |
|
|
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5208252 |
Russell et al. |
May 1993 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
A0285284 |
Oct 1988 |
EPX |
A3242344 |
May 1984 |
DEX |
Non-Patent Literature Citations (1)
Entry |
Biochem J., Sim, et al. "Metabolics of procainamide and practolol inhibit complement components C3 and C4". p. 324, 1988. |